Repligen Q4 Earnings Call Highlights

Core Insights - Repligen reported strong fourth-quarter results with adjusted gross profit of $104 million and adjusted gross margin of 52.4%, reflecting a year-over-year increase of 170 basis points, driven by volume leverage and pricing [1] - The company achieved fourth-quarter revenue of $198 million and full-year revenue of $738 million, exceeding the high end of its October guidance [5] - For 2026, Repligen provided guidance of $810 million to $840 million in revenue, indicating a growth rate of 10% to 14% [11] Financial Performance - Adjusted operating income for the fourth quarter was $30 million, resulting in a 15% adjusted operating margin, while the full-year adjusted operating income was $102 million with a margin of 13.8% [6] - Adjusted diluted EPS for the fourth quarter was $0.49, up from $0.44 in the prior-year quarter, and for the full year, it was $1.71, representing a 9% year-over-year increase [7] - The company ended the fourth quarter with $768 million in cash and marketable securities, an increase of $90 million sequentially [7] Growth Drivers - Fourth-quarter growth was supported by consumables, which saw over 20% growth, while capital equipment remained flat year-over-year [3] - The biopharma segment grew over 20% year-over-year, with contributions from both pharma and emerging biotech customers [10] - Chromatography and proteins segments grew by 25% and 31% respectively for the year, exceeding prior expectations [9] Regional Performance - North America accounted for approximately 47% of revenue, EMEA 34%, and Asia Pacific and the rest of the world 19% in the fourth quarter [2] - EMEA region experienced growth of more than 20%, while Asia Pacific grew in the high teens [2] Future Outlook - The company anticipates adjusted gross margin for 2026 to be between 53.6% and 54.1%, with adjusted operating income projected at $122 million to $130 million [13] - Management highlighted potential headwinds from a gene therapy platform and ongoing macroeconomic uncertainties [5][11] - The company expects normal seasonality in revenue distribution, with about 48% of revenue expected in the first half of the year [16]